New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...

Patients were required to have a confirmed diagnosis of psoriasis vulgaris for at least 1 year, be aged 18 years or older, and proficient in Polish. Those with other chronic dermatologic ...

Dovobet ® is a compounded combination of calcipotriol [also calcipotriene] and betamethasone diproprionate, and is used for psoriasis vulgaris once daily. For this photo case presentation ...

Learn more about whether Biogen Inc. or Natera, Inc. is a better investment based on AAII's A+ Investor grades, which compare ...

is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA). Biocon Biologics previously notified the stock exchanges on August 29, 2024, that the company had entered into a ...

She had had an extensive psoriasis for the past 22 years, and in 1954, pemphigus vulgaris developed. This was treated with hydrocortisone, with complete involution of the pemphigus and about 60 ...

Yoshindo Inc. Ustekinumab, which is a monoclonal antibody, is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA).

Arctic therapeutics raises funding from EIC Fund, Kaldbakur, and Sanos Group to advance its dementia treatment, AT-001, and acne drug, AT-004. The company aims to transform the treatment landscape for ...

is approved for the treatment of Psoriasis Vulgaris and Psoriatic Arthritis (PsA). Read also: Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, Japan Biocon Biologics had ...

St Agnes College hosted a seminar on Skin Health Awareness among Teenagers on January 18 organized by the department of ...

Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a €26.5 million oversubscribed Series A financing from a broad syndicate of ...

This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...